The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Notes landmark agreement with U.S. government: Says voluntary agreement provides greater clarity; reduces uncertainty around tariffs and pricing; allows investment in future innovation and growth.

Pfizer CEO Albert Bourla said the company was on track with new products, but shares fell as it signaled lower revenues in 2026 ...

Pfizer stands as one of the largest drug makers in the world. It faces normal industry challenges, but it also has a lofty payout ratio. Its latest acquisition shows what it is capable of doing to get ...